Everolimus in the Treatment of Metastatic Breast Cancer | Zendy

Melanie Royce | Zendy; Diaa Osman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Everolimus in the Treatment of Metastatic Breast Cancer

Author(s) -

Melanie Royce,

Diaa Osman

Publication year - 2015

Publication title -

breast cancer basic and clinical research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.741

H-Index - 23

ISSN - 1178-2234

DOI - 10.4137/bcbcr.s29268

Subject(s) - everolimus , discovery and development of mtor inhibitors , breast cancer , metastatic breast cancer , medicine , pi3k/akt/mtor pathway , clinical trial , oncology , cancer , disease , bioinformatics , cancer research , signal transduction , biology , biochemistry

The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor-positive, human epidermal growth factor receptor-negative metastatic disease that has progressed after prior endocrine therapy. This review summarizes findings from clinical trials that have demonstrated the benefit of everolimus in metastatic breast cancer and highlights some new research directions utilizing everolimus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research